The incidence of malignant melanoma is increasing at a rate greater than that of any other human cancer. The etiologic factors contributing to the development of malanoma are multiple; genetic factors may be considered to be of primary importance with secondary contributions from carcinogenic stimuli. Several oncogenes and tumor suppressor genes have been implicated in melanoma progression, however, no particular amplification, mutation, or rearrangement of these genes has been found to contribute to transformation. To implicate an oncogene in the onset of malanoma development, a gain of function, most likely through mutation of an existing gene, is required. Conversely, inactivation of a tumor suppressor gene can be achieved through a number of different mechanisms, including mutation, deletion, or rearrangement. Transgenic mice provide model systems that can be used to broaden the understanding of human diseases. Currently, very few experimental animal models exist for melanoma formation and all mouse models require a combination of carcinogen and UV treatments. In contrast, a lone of transgenic mice was generated in the laboratory that displays a phenotype similar to melanoma without exposure to any known stimuli. The animals showed areas of pigmented spots on the ear at 10 to 14 days after birth followed by appearance of raised pigmented lesions by about 2 to 3 months of age. The majority of the animals died before one year of age. They propose a set of experiments to study the host gene(s) which was interrupted by the insertion of the transgene. This interruption may have activated an """"""""off"""""""" oncogene to the """"""""on"""""""" state, thus activating its expression and resulting in the transformation of cells. Alternatively, their transgene may have interrupted a tumor suppressor gene, thus leading to unrestricted expansion of targeted cells. A third possibility is specific interaction(s) transpired between the transgene and the interrupted host sequences, such interaction(s) resulted in tumor development. To distinguish among these possibilities, they propose a set of experiments to isolate and characterize the gene product of the disrupted host sequences. Analysis of the DNA sequences from cDNA clones will be done first to see if the sequences is known or novel. If the DNA sequences are of a known """"""""oncogene"""""""" or """"""""tumor suppressor gene"""""""", regulation of its expression will be examined in the system. If the DNA sequences have not been described, in vitro biological assays will be done to see if it is a general or specific """"""""oncogene"""""""" or """"""""tumor suppressor gene"""""""". Regulation of expression of this putative gene in normal and tumor cells will be done. Involvement of this putative gene in human melanoma tumors will be studied. The long term goal is to use this line of transgenic mice as a model system for the molecular, and genetic characterization of the development of melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA074077-04S1
Application #
6479310
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mietz, Judy
Project Start
1997-12-08
Project End
2002-11-30
Budget Start
2001-07-01
Budget End
2001-11-30
Support Year
4
Fiscal Year
2001
Total Cost
$66,433
Indirect Cost
Name
Rutgers University
Department
Biology
Type
Schools of Pharmacy
DUNS #
038633251
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Mairhofer, David G; Ortner, Daniela; Tripp, Christoph H et al. (2015) Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. J Invest Dermatol 135:2785-2793
Wall, Brian A; Wangari-Talbot, Janet; Shin, Seung S et al. (2014) Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27:263-74
Martino, J J; Wall, B A; Mastrantoni, E et al. (2013) Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 32:4366-76
Wangari-Talbot, Janet; Wall, Brian A; Goydos, James S et al. (2012) Functional effects of GRM1 suppression in human melanoma cells. Mol Cancer Res 10:1440-50
Lee, Hwa Jin; Wall, Brian A; Wangari-Talbot, Janet et al. (2011) Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res 17:7080-92
Wangari-Talbot, Janet; Goydos, James; Chen, Suzie (2010) Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals (Basel) 3:2821-2837
Lee, Hwa Jin; Wall, Brian; Chen, Suzie (2008) G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res 21:415-28
Namkoong, Jin; Martino, Jeffrey J; Chen, Suzie (2006) From existing therapies to novel targets: a current view on melanoma. Front Biosci 11:2081-92
Marin, Yari E; Chen, Suzie (2004) Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med 82:735-49
Cohen-Solal, Karine A; Sood, Raman; Marin, Yari et al. (2003) Identification and characterization of mouse Rab32 by mRNA and protein expression analysis. Biochim Biophys Acta 1651:68-75

Showing the most recent 10 out of 14 publications